Attached files
| file | filename |
|---|---|
| EX-99.1 - EX-99.1 - ALDER BIOPHARMACEUTICALS INC | aldr-ex991_201505078.htm |
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d)
of the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): May 7, 2015
Alder BioPharmaceuticals, Inc.
(Exact name of registrant as specified in its charter)
|
Delaware |
|
001-36431 |
|
90-0134860 |
|
(State or other jurisdiction |
|
(Commission |
|
(IRS Employer |
|
11804 North Creek Parkway South Bothell, WA |
|
98011 |
|
(Address of principal executive offices) |
|
(Zip Code) |
(425) 205-2900
Registrant’s telephone number, including area code:
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
|
¨ |
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) |
|
¨ |
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) |
|
¨ |
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) |
|
¨ |
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |
Item 2.02 Results of Operations and Financial Condition.
On May 7, 2015, Alder BioPharmaceuticals, Inc. issued a press release announcing financial results for the first quarter ended March 31, 2015. A copy of the press release is furnished herewith as Exhibit 99.1 and incorporated into this Form 8-K by reference.
The information included under Item 2.02 of this report is being furnished and shall not be deemed ‘‘filed’’ for purposes of Section 18 of the Securities Exchange Act of 1934, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, except as shall be expressly set forth by specific reference in such filing.
Item 9.01 Financial Statements and Exhibits.
(d) Exhibits.
|
Exhibit No. |
|
Description |
|
99.1 |
|
Press Release of Alder BioPharmaceuticals, Inc. dated May 7, 2015 |
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
|
|
|
Alder BioPharmaceuticals, Inc. |
|
|
|
|
|
|
|
Dated: May 7, 2015 |
|
|
|
|
|
|
By: |
/s/ Randall C. Schatzman |
|
|
|
|
Randall C. Schatzman, Ph.D. |
|
|
|
|
President and Chief Executive Officer |
INDEX TO EXHIBITS
|
Exhibit No. |
|
Description |
|
99.1 |
|
Press Release of Alder BioPharmaceuticals, Inc. dated May 7, 2015 |